{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"172","value":"4.904"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"}],"units":"Participants"}],"title":"Cycle1 (day 15)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"174","value":"6.272"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"}],"units":"Participants"}],"title":"Cycle1 (day 29)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"}],"units":"Participants"}],"description":"Predose concentration during multiple dosing.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Axitinib PK concentration analysis set: all participants who received at least one dose of study drug and have at least one post-dose concentration above lower limit of quantitation (LLQ) for axitinib. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies number of participants evaluable for the specified rows. This outcome measure was not planned to be analyzed in ''Sunitinib'' reporting group.","reportingStatus":"POSTED","timeFrame":"Pre dose (0 hour) on day 15 and 29 of cycle 1 (each cycle= 6 weeks)","title":"Ctrough of Axitinib","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}